The monoclonal neutralising antibody therapy co-developed by Brii, Tsinghua University and the Third People’s Hospital of Shenzhen. Photo: AP
exclusive | China’s first home-grown Covid-19 medication expected as early as January, says Hong Kong-listed Brii Biosciences
- The drug is going through an additional government review and is likely to be launched in the first quarter of 2022, Brii CEO and co-founder says
- FDA approval for emergency use is likely to come next month
The monoclonal neutralising antibody therapy co-developed by Brii, Tsinghua University and the Third People’s Hospital of Shenzhen. Photo: AP
